OCX OncoCyte Corp
Price (delayed)
$3.19
Market cap
$42.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4,591.01
Enterprise value
$35.36M
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical
Highlights
The company's EPS rose by 47% YoY and by 47% QoQ
OncoCyte's net income has increased by 40% YoY and by 9% QoQ
OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY
OCX's quick ratio has surged by 72% since the previous quarter but it is down by 45% year-on-year
OncoCyte's gross profit has shrunk by 73% QoQ
OCX's gross margin has dropped by 63% since the previous quarter
Key stats
What are the main financial stats of OCX
Market
Valuations
Earnings
Shares outstanding
13.37M
Market cap
$42.65M
Enterprise value
$35.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
40.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.56
Revenue
$1.02M
EBIT
-$36.28M
EBITDA
-$34.87M
Free cash flow
-$16.89M
Per share
Balance sheet
Liquidity
EPS
-$4,591.01
Free cash flow per share
-$1.31
Book value per share
$1.7
Revenue per share
$0.08
TBVPS
$1.41
Total assets
$74.72M
Total liabilities
$52.02M
Debt
$3.67M
Equity
$22.7M
Working capital
$2.77M
Debt to equity
0.16
Current ratio
1.38
Quick ratio
1.53
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
-3,408.4%
Gross margin
8.1%
Net margin
-3,552.9%
Operating margin
-3,576.8%
Return on assets
-48.6%
Return on equity
-159.2%
Return on invested capital
-1,101.1%
Return on capital employed
-53.7%
Return on sales
-3,546.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCX stock price
How has the OncoCyte stock price performed over time
Intraday
4.59%
1 week
1.59%
1 month
4.59%
1 year
-5.34%
YTD
27.6%
QTD
8.14%
Financial performance
How have OncoCyte's revenue and profit performed over time
Revenue
$1.02M
Gross profit
$83,000
Operating income
-$36.59M
Net income
-$36.35M
Gross margin
8.1%
Net margin
-3,552.9%
The operating margin has shrunk by 149% YoY and by 23% QoQ
The operating income has dropped by 132% year-on-year but it has grown by 9% since the previous quarter
OncoCyte's gross profit has shrunk by 73% QoQ
OCX's gross margin has dropped by 63% since the previous quarter
Growth
What is OncoCyte's growth rate over time
Valuation
What is OncoCyte stock price valuation
P/E
N/A
P/B
1.88
P/S
40.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.56
The company's EPS rose by 47% YoY and by 47% QoQ
OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY
The stock's price to book (P/B) is 34% more than its last 4 quarters average of 1.4 but 28% less than its 5-year quarterly average of 2.6
The price to sales (P/S) is 94% less than the 5-year quarterly average of 701.5 but 89% more than the last 4 quarters average of 21.2
The revenue has decreased by 26% QoQ and by 7% YoY
Efficiency
How efficient is OncoCyte business performance
The company's return on sales rose by 35% YoY but it fell by 22% QoQ
OCX's ROIC is down by 34% year-on-year and by 15% since the previous quarter
The company's return on equity fell by 26% YoY and by 11% QoQ
OCX's return on assets is up by 14% year-on-year and by 6% since the previous quarter
Dividends
What is OCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCX.
Financial health
How did OncoCyte financials performed over time
OCX's total assets is 44% greater than its total liabilities
The current ratio has soared by 77% from the previous quarter but it has contracted by 50% YoY
OCX's quick ratio has surged by 72% since the previous quarter but it is down by 45% year-on-year
OCX's debt is 84% smaller than its equity
The debt to equity has surged by 129% year-on-year but it has declined by 45% since the previous quarter
OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.